Please select the option that best describes you:
Would you utilize Breast Cancer Index in patients with ER+ HER2+ breast cancer to guide whether or not to extend adjuvant endocrine therapy?
Should BCI only be used for HER2- patients?
Should BCI only be used for HER2- patients?